Measure would save money for Utah patients and taxpayers.
We appreciate President Trump’s continued focus on the country’s drug pricing crisis. But, two years into his term, prices are still going up, patients are still struggling, and Big Pharma is breaking records lobbying Congress to keep it that way.
Patient whose Part B drug costs led to bankruptcy supports Trump Administration and urges Congress to support the International Pricing Index.
The drug lobby’s arguments against holding down prices in Medicare Part B just don’t add up.
3 questions to ask the drug lobby about Medicare Part B
Patients For Affordable Drugs Now Takes Major Action in Support of International Pricing Index and Medicare Part B Reforms.
More than 1,500 patient advocates agree: the Department of Health and Human Services’ proposal to lower drug prices in Medicare Part B must move forward.
Voters DO NOT buy Big Pharma’s spin that the IPI will harm patient access to drugs
Under the draft proposal from the Department of Health and Human Services, prices for expensive infused drugs administered in physician offices and hospitals would be brought more in line with what people in other wealthy nations pay.
As for me, instead of having a retirement savings we were on track to have before my illness, we are living month to month on social security and now on my income from returning to work.
The plan will allow us to negotiate better on the price of drugs and will effectively bring our costs down by over 50 percent. That would make a difference for my peace of mind and the health of many Americans like me.
Pharma front group bankrolls $1 million ad buy to smear Part B proposal.
Patients won. Drug prices won.
The drug lobby contemplates a strange future in which the left aligns with Trump to bring down drug prices.
One of the most difficult parts around having this condition is how quickly medical costs –– especially the cost of prescription drugs –– add up.